NeuroPace (NPCE) Profit After Tax Growth (3y) (2023 - 2026)
NeuroPace (NPCE) Profit After Tax Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.21 Bn | 193.61 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 126.18 Bn | 122.71 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.54 Bn | 109.32 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.16 Bn | 72.63 Bn | 3.85 Bn | 49.66% |
| 5 | Edwards Lifesciences | 52.05 Bn | 47.79 Bn | 1.35 Bn | -7.65% |
| 6 | Dexcom | 34.46 Bn | 32.52 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.73 Bn | 31.63 Bn | 2.18 Bn | 9.79% |
| 8 | Koninklijke Philips | 26.33 Bn | 23.01 Bn | 4.55 Bn | 97.37% |
| 9 | Steris | 23.09 Bn | 22.61 Bn | 684.20 Mn | 15.46% |
| 10 | NeuroPace | 476.10 Mn | 424.40 Mn | 18.91 Mn | 12.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.08% |
| Mar 31, 2026 | 13.61% |
| Dec 31, 2025 | 35.32% |
| Sep 30, 2025 | 33.08% |
| Jun 30, 2025 | 11.99% |
| Mar 31, 2025 | 16.85% |
| Dec 31, 2024 | 21.11% |
| Sep 30, 2024 | 12.22% |
| Jun 30, 2024 | 4.00% |
| Mar 31, 2024 | -0.43% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -20.75% |
| Jun 30, 2023 | -1.24% |
| Mar 31, 2023 | -15.46% |